Research programme: TANA inhibitors - ImStar Therapeutics
Latest Information Update: 28 Dec 2017
At a glance
- Originator ImStar Therapeutics
- Class
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for research development in Alzheimer's-disease in Canada
- 28 Dec 2017 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in Canada
- 28 Dec 2017 No recent reports of development identified for research development in Dementia in Canada